Detalhe da pesquisa
1.
Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.
Liver Int
; 43(8): 1663-1676, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183524
2.
A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction.
J Viral Hepat
; 28(2): 410-419, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33185325
3.
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study.
Liver Int
; 41(2): 295-299, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33217778
4.
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
J Hepatol
; 64(1): 19-28, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26321288
5.
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Lancet Infect Dis
; 19(3): 275-286, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30833068
6.
Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
J Gastrointestin Liver Dis
; 22(1): 27-32, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23539387
7.
Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
J Gastrointestin Liver Dis
; 18(4): 425-31, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20076814